Autonomous implant for cancer treatment


© Fraunhofer EMFT
Microfluidic system for tumor therapy

When a cancer tumor starts to metastasize, the chances of the patient recovering get significantly worse. Metastasis is particularly dangerous in the case of malignant tumors: in spite of numerous attempts, no effective treatment has yet been found to stop the process. Fraunhofer EMFT pursued a new, innovative approach with its partner under the industrial project μP Brain Test. The aim of the project was to provide a silicon, bubble-tolerant MEMS micropump developed by Fraunhofer EMFT (TUDOS – Tumor Dosing) as the core element of an autonomous implant to combat meningeal metastasis. By means of metronomic dosing to the microliter, it is possible to maintain the therapeutic level as the basis for an entirely modernized and more patient-friendly cancer treatment.


In addition to precise analysis of dosing stability in long-term testing of the pumped cytostatic, the interaction between the micropump and the active agent was investigated so as to prepare micropumps for medical examinations. This progress could be a key factor in future: after all, metastases are still the biggest stumbling block in the fight for survival against cancer.